



Nanofibers and Nanoparticles from Marine Biomaterials for Tissue Engineering, Drug Delivery and Other Biomedical Applications

Guest Editors:

Prof. Dr. Vassilios Roussis

Department of Pharmacy,
National and Kapodistrian
University of Athens, 157 72
Athens, Greece

Dr. Efstathia Ioannou

Department of Pharmacy,
National and Kapodistrian
University of Athens, 157 72
Athens, Greece

Dr. Stefanos Kikionis

Department of Pharmacy,
National and Kapodistrian
University of Athens, Athens,
Greece

Deadline for manuscript
submissions:

closed (20 December 2022)

Message from the Guest Editors

Nanotechnology represents an emerging technological field in medicine and biomedical engineering. Nanostructured particulate and fibrous systems are attracting constantly increasing attention for the development of novel biomedical systems in tissue-engineering and drug-delivery applications. Various natural and synthetic polymers can be engineered in functionalized and modified hybrid nanostructures with the desired and necessary properties for targeted bioapplications.

Marine biopolymers are considered abundant, cost-efficient, and non-toxic materials, representing a rapidly growing sector of materials in the biomedical field, due to their high biocompatibility and biodegradability, and inherent biological properties.

This Special Issue aims to include original research articles and reviews on the design, development, and detailed characterization of marine-based nanostructured biomaterials with the potential for utilization in various biomedical applications as drug-release modifiers, bioadhesives, cell scaffolds, coatings, wound-dressing materials and tissue-engineering scaffolds.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

Contact Us

Marine Drugs Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](https://twitter.com/Marine_Drugs)